EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Modern Clinical Trials: Seamless Designs and Master Protocols

Abigail Burdon iD, Thomas Jaki, Xijin Chen, Pavel Mozgunov, Haiyan Zheng, Richard Baird

Cancer Medicine · 2026-05 · 15 (5)

DOI: 10.1002/cam4.71858 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 23.04.2026. Verfasst von Abigail Burdon und 5 weiteren Autor:innen. Beteiligte Einrichtung: MRC Biostatistics Unit, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Research Design, Neoplasms, Clinical Trials as Topic, Drug Development. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 Framework Programme, National Institute for Health and Care Research, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Drug development is often inefficient, costly and lengthy, yet it is essential for evaluating the safety and efficacy of new interventions. Compared with other disease areas, this is particularly true for Phase II/III cancer clinical trials where many drug candidates fail to advance and reduced regulatory approvals are being seen. In response to these challenges, seamless clinical trials and master protocols have emerged to streamline the drug development process.

Methods

Seamless clinical trials, characterised by their ability to transition seamlessly from one phase to another, can lead to accelerating the development of promising therapies while Master protocols provide a framework for investigating multiple treatment options and patient subgroups within a single trial.

Results

We discuss the advantages of these methods through real trial examples and the principles that lead to their success while also acknowledging the associated regulatory considerations and challenges.

Conclusion

Seamless designs and master protocols have the potential to improve confirmatory clinical trials. In the disease area of cancer, this ultimately means that patients can receive life‐saving treatments sooner.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignNeoplasmsClinical Trials as TopicDrug DevelopmentHumansClinical Trials, Phase II as TopicAntineoplastic Agents

Stichwörter der Autor:innen

adaptive designsefficient trialsinterim analysismaster protocolsseamless phase II/III

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
  • University of Regensburg, Regensburg, Germany.
  • Department of Mathematical Sciences, University of Bath, Bath, UK.
  • Department of Oncology, University of Cambridge, Cambridge, UK.

ORCID-Profile: Abigail Burdon

Förderung

  • Horizon 2020 Framework Programme
  • National Institute for Health and Care Research
  • Cancer Research UK
  • Medical Research Council

Zitieren

APA

Burdon, A., Jaki, T., Chen, X., Mozgunov, P., Zheng, H., & Baird, R. (2026). Modern Clinical Trials: Seamless Designs and Master Protocols. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71858

Vancouver

Burdon A, Jaki T, Chen X, Mozgunov P, Zheng H, Baird R. Modern Clinical Trials: Seamless Designs and Master Protocols. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71858

BibTeX
@article{Burdon2026,
  author = {Burdon, Abigail and Jaki, Thomas and Chen, Xijin and Mozgunov, Pavel and Zheng, Haiyan and Baird, Richard},
  title = {Modern Clinical Trials: Seamless Designs and Master Protocols},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cam4.71858}
}
Kostenlos starten →